Lyndra Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Lyndra Therapeutics's estimated annual revenue is currently $17.2M per year.
- Lyndra Therapeutics's estimated revenue per employee is $155,000
- Lyndra Therapeutics's total funding is $163.3M.
Employee Data
- Lyndra Therapeutics has 111 Employees.
- Lyndra Therapeutics grew their employee count by -38% last year.
Lyndra Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Chief Financial Officer | Reveal Email/Phone |
2 | Chief Technology Officer | Reveal Email/Phone |
3 | Chief Staff & Head Government Affairs/Corporate Development | Reveal Email/Phone |
4 | VP Engineering and Industrialization | Reveal Email/Phone |
5 | VP Clinical Development | Reveal Email/Phone |
6 | SVP Portfolio and Commercial Strategy, Oral Weekly Risperidone Program Leader | Reveal Email/Phone |
7 | VP, Technical Operations | Reveal Email/Phone |
8 | VP Quality Assurance | Reveal Email/Phone |
9 | SVP, Quality and Compliance | Reveal Email/Phone |
10 | VP, Data Compliance & Information Technology | Reveal Email/Phone |
Lyndra Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Lyndra Therapeutics?
TRANSFORMING THE WAY WE TAKE MEDICINE FOR A HEALTHIER WORLD ULTRA-LONG-ACTING ORAL DOSING IS ACHIEVABLE Our Team has developed the first ultra-long-acting pill that lasts a week or longer and can provide a wide range of medicines in a familiar oral capsule form. Once inside the stomach, the capsule delivers steady amounts of medicine for seven days or more. Our once-weekly product has safely demonstrated gastric residence with predictable pharmacokinetics in humans. There are no other oral products which provide ultra-long-acting therapeutic coverage or a controlled, steady delivery of medicine which can reduce side effects and improve drug efficacy, resulting in measurable health outcomes. At Lyndra, we ask “What if we stopped trying to change the patient and changed the pill instead?"​ Want to learn more? Please visit our website or contact us at info@lyndra.com. INSPIRED to Join Our Team? Check us out and apply! www.lyndra.com/join-our-team/ At Lyndra Therapeutics, we are INSPIRED by team members who are excited by innovation and growth, demonstrate strong technical expertise, and live our values. We are looking for people who will bring fresh ideas based on experience and who lead by adapting to the fast pace of an emerging biotech. In preparation for Phase 2 clinical development, we are looking to build our team in key areas in the near term : Clinical, Medical, Pre-clinical, Formulation, Process Development, Mechanical Engineering, and Manufacturing.
keywords:N/A$163.3M
Total Funding
111
Number of Employees
$17.2M
Revenue (est)
-38%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Lyndra Therapeutics News
In July 2019, Lyndra Therapeutics, a biopharmaceutical company, announced a partnership with Gilead Sciences, Inc., a biotechnology company,...
... of thyroid-related diseases worldwide and robust R&D activities | Pfizer Inc., McGuff Pharmaceuticals, Inc., Lyndra Therapeutics, Inc.
... as well as chair of the board of SQZ Biotech, executive chair of Lyndra Therapeutics, and manages the LS Polaris Innovation Fund.
Lyndra Therapeutics, a Watertown, Mass.-based clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, closed a $60.5m Series C financing. The round was led by new investor, AIG Investments, an af ...
Lyndra Therapeutics, a clinical-stage biotechnology company pioneering a novel technology platform that transforms daily pills into once-weekly to monthly oral treatment options, today announced the closing of its $60.5 million Series C financing. The proceeds of the round, led by new investor, ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $31.1M | 115 | -17% | N/A |
#2 | N/A | 116 | 2% | N/A |
#3 | $23.5M | 117 | 52% | N/A |
#4 | $15M | 119 | -37% | $217.5M |
#5 | $25.2M | 120 | 6% | N/A |